Argus analyst Jasper Hellweg raised the firm’s price target on United Therapeutics (UTHR) to $400 from $360 and keeps a Buy rating on the shares. The firm is positive on the strong performance of both Tyvaso DPI and Nebulized Tyvaso, as well as other products in the company’s portfolio, the promising organ manufacturing and transplant program, and the company’s solid balance sheet, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $600 from $575 at Oppenheimer
- United Therapeutics price target raised to $344 from $319 at Ladenburg
- United Therapeutics price target raised to $425 from $400 at H.C. Wainwright
- United Therapeutics Reports Strong Q3 2024 Results
- United Therapeutics reports Q3 EPS $6.93, consensus $6.42